News Article | April 17, 2017
Global Lyme Alliance (GLA), the leading Lyme and tick-borne disease nonprofit dedicated to conquering Lyme through research and education, announced today that its Greenwich Gala, held Saturday April 1 at the Hyatt Regency Greenwich, raised nearly $800,000 to fund research and ultimately a cure for Lyme and other tick-borne illnesses. “Huge thanks to all those who made the Gala such a wonderful success—our special guests, honorees, co-chairs, as well as the many generous donors who invested their time and funds in the fight against tick-borne disease,” said Scott Santarella, GLA’s CEO. Gretchen Carlson, TV journalist and female empowerment advocate, served as master of ceremonies for the event, which was attended by over 450 guests, including U.S. Senator Richard Blumenthal, U.S. Rep. Jim Himes, novelist Jay McInerney, UFC lightweight fighter Jim Miller, prominent business leaders, esteemed scientists and philanthropists. The event was co-chaired by Robyn Carpenter, Heather Glass, Amy Tambini and Tara Vessels. In her opening remarks, Carlson talked about being treated for Lyme disease five years ago after initially being misdiagnosed. “I’m one of the lucky ones,” she said. “I don’t have any symptoms of the chronic disease at this point. But so many other people are affected by this [disease] in such a serious way.” Senator Blumenthal, a long-time GLA supporter, spoke about how everyone in the room was “touched by this insidious, pernicious disease.” He rightly termed it a pandemic and called for greater attention to the issue by the federal government. Honored at the event was Dr. Harriet Kotsoris, who received the Lauren F. Brooks Hope Award for her pioneering 10 years as GLA’s Chief Scientific Officer and founder of its Scientific Advisory Board. “Harriet created the framework from which all future research can flourish, establishing a newfound credibility and understanding of Lyme and tick-borne diseases,” said GLA Vice Chair Diane Blanchard, who presented Dr. Kotsoris with the award. Singer-songwriter Marina Morgan received GLA’s Star Light Award, created to honor individuals who have lent their voices to the fight against Lyme disease. Morgan—featured by national radio host Elvis Duran as his December “Artist of the Month”—said she was inspired by her health struggles with Lyme-related pain and fatigue to write her powerful song, “Paralyzed.” The Staten Island, NY resident said she wanted to “spread hope that there is a light at the end of the tunnel and encourage people to never give up.” Morgan received a standing ovation after she performed her song live. In one of the more emotional speeches of the night, Tara Vessels, one of the event co-chairs, talked about how her son getting Lyme disease at age 12 changed his life and those of his parents. Vessels, her voice cracking with emotion, described the family’s ongoing search for treatment and the difficulties her son was forced to face. “Even the most resilient warrior can feel like giving up the fight," she said. This disease completely wears you down." Gala sponsors included Withersworldwide, FS Investments, Greenwich Hospital, Luxe.Interiors + Design, WIMCO Villas, Wheels Up, Fairfield County Look and Tradewind Aviation. In addition to the Gala, on Friday and Saturday, GLA hosted its annual closed-door Research Symposium for 25 eminent members of the scientific community who are either current or past GLA grant recipients or members of GLA’s Scientific Advisory Board. Global Lyme Alliance will hold another major fundraiser in New York City on Wednesday, October 11at Cipriani 42nd Street. _______________________________________________________________________________________________________________ ABOUT GLOBAL LYME ALLIANCE Global Lyme Alliance is the leading private nonprofit dedicated to conquering Lyme through research and education. The 501(c)(3) is headquartered in Greenwich, CT. For more information go to GLA.org.
News Article | May 5, 2017
Gerald B. Harris, DO, ABAM, DFASAM, Addiction Medicine Specialist with his own practice, and affiliated with the Banner Boswell Medical Center, has been named a 2017 Top Doctor in Glendale, Arizona. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Gerald B. Harris is a highly respected and experienced physician, having been in practice for more than 17 years. His medical career commenced in 1999, when he graduated from the Western University of Health Sciences College of Osteopathic Medicine of the Pacific in Pomona, California. This was followed by a residency at Greenwich Hospital, prior to entering private practice. As an experienced physician, Dr. Harris treats adult patients of all ages for a variety of conditions, but he is especially renowned as an addiction medicine specialist. He provides expert treatment for addiction to opiates and alcohol, and is also a specialist in weight loss treatments, providing lifestyle and nutrition advice, as well as medical assistance where required. Dr. Harris also carries out physicals for work, schools, and for insurance purposes. Dr. Harris has earned the coveted title of Distinguished Fellow of the American Society of Addiction Medicine, and is noted for his holistic approach to medicine, including the use of acupuncture, and for helping patients manage their own health conditions. This empowering philosophy, allied with his dedication and expertise, makes Dr. Gerald B. Harris a very deserving winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.
Finnerup N.B.,University of Aarhus |
Attal N.,French Institute of Health and Medical Research |
Attal N.,University of Versailles |
Haroutounian S.,University of Washington |
And 22 more authors.
The Lancet Neurology | Year: 2015
Background: New drug treatments, clinical trials, and standards of quality for assessment of evidence justify an update of evidence-based recommendations for the pharmacological treatment of neuropathic pain. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), we revised the Special Interest Group on Neuropathic Pain (NeuPSIG) recommendations for the pharmacotherapy of neuropathic pain based on the results of a systematic review and meta-analysis. Methods: Between April, 2013, and January, 2014, NeuPSIG of the International Association for the Study of Pain did a systematic review and meta-analysis of randomised, double-blind studies of oral and topical pharmacotherapy for neuropathic pain, including studies published in peer-reviewed journals since January, 1966, and unpublished trials retrieved from ClinicalTrials.gov and websites of pharmaceutical companies. We used number needed to treat (NNT) for 50% pain relief as a primary measure and assessed publication bias; NNT was calculated with the fixed-effects Mantel-Haenszel method. Findings: 229 studies were included in the meta-analysis. Analysis of publication bias suggested a 10% overstatement of treatment effects. Studies published in peer-reviewed journals reported greater effects than did unpublished studies (r2 9·3%, p=0·009). Trial outcomes were generally modest: in particular, combined NNTs were 6·4 (95% CI 5·2-8·4) for serotonin-noradrenaline reuptake inhibitors, mainly including duloxetine (nine of 14 studies); 7·7 (6·5-9·4) for pregabalin; 7·2 (5·9-9·21) for gabapentin, including gabapentin extended release and enacarbil; and 10·6 (7·4-19·0) for capsaicin high-concentration patches. NNTs were lower for tricyclic antidepressants, strong opioids, tramadol, and botulinum toxin A, and undetermined for lidocaine patches. Based on GRADE, final quality of evidence was moderate or high for all treatments apart from lidocaine patches; tolerability and safety, and values and preferences were higher for topical drugs; and cost was lower for tricyclic antidepressants and tramadol. These findings permitted a strong recommendation for use and proposal as first-line treatment in neuropathic pain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concentration patches, and tramadol; and a weak recommendation for use and proposal as third line for strong opioids and botulinum toxin A. Topical agents and botulinum toxin A are recommended for peripheral neuropathic pain only. Interpretation: Our results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain. Inadequate response to drug treatments constitutes a substantial unmet need in patients with neuropathic pain. Modest efficacy, large placebo responses, heterogeneous diagnostic criteria, and poor phenotypic profiling probably account for moderate trial outcomes and should be taken into account in future studies. Funding: NeuPSIG of the International Association for the Study of Pain. © 2015 Elsevier Ltd.
Wrigley P.J.,University of Sydney |
Gustin S.M.,University of Sydney |
McIndoe L.N.,University of Sydney |
Chakiath R.J.,University of Sydney |
And 3 more authors.
Pain | Year: 2013
Neuropathic pain remains one of the most difficult consequences of spinal cord injury (SCI) to manage. It is a major cause of suffering and adds to the physical, emotional, and societal impact of the injury. Despite the use of the best available treatments, two thirds of people experiencing neuropathic pain after SCI do not achieve satisfactory pain relief. This study was undertaken in response to a recent clinical trial reporting short-term, clinically significant reductions in neuropathic SCI pain with primary motor cortex transcranial direct current stimulation (tDCS). In this investigation, we aimed to build on this previous clinical trial by extending the assessment period to determine the short-, medium-, and long-term efficacy of tDCS for the treatment of neuropathic pain after SCI. We found that, contrary to previous reports, after 5 tDCS treatment periods, mean pain intensity and unpleasantness rating were not significantly different from initial assessment. That is, in this trial tDCS did not provide any pain relief in subjects with neuropathic SCI pain (n = 10). A similar lack of effect was also seen after sham treatment. Because the injury duration in this study was significantly greater than that of previous investigations, it is possible that tDCS is an effective analgesic only in individuals with relatively recent injuries and pain. Future investigations comparing a range of injury durations are required if we are to determine whether this is indeed the case. © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Garland E.M.,Vanderbilt University |
Hooper W.B.,Greenwich Hospital |
Robertson D.,Vanderbilt University
Handbook of Clinical Neurology | Year: 2013
A 1925 report by Bradbury and Eggleston first described patients with extreme orthostatic hypotension and a low, steady heart rate. Evidence accumulated over the next two decades that patients with orthostatic hypotension include those with pure autonomic failure (PAF), characterized by isolated peripheral autonomic dysfunction and decreased norepinephrine synthesis; multiple system atrophy (MSA) with symptoms of a central Parkinson-like syndrome and normal resting plasma norepinephrine; and Parkinson's disease (PD), with lesions in postganglionic noradrenergic neurons and signs of autonomic dysfunction. All three disorders are classified as α-synucleinopathies. Insoluble deposits of α-synuclein are found in glia in MSA, whereas they take the form of neuronal cytoplasmic inclusions called Lewy bodies in PAF and PD. The exact relationship between α-synuclein deposits and the pathology remains undetermined.PAF occurs sporadically, and progresses slowly with a relatively good prognosis. However, it has been proposed that some cases of PAF may develop a central neurodegenerative disorder. Differentiation between PAF, MSA, and PD with autonomic failure can be facilitated by a number of biochemical and functional tests and by imaging studies. Cardiac sympathetic innervation is generally intact in MSA but decreased or absent in Parkinson's disease with autonomic failure and PAF.Treatment of PAF is directed at relieving symptoms with nonpharmacological interventions and with medications producing volume expansion and vasoconstriction. Future studies should focus on determining the factors that lead to central rather than solely peripheral neurodegeneration. © 2013 Elsevier B.V.
Sabetta J.R.,Yale University |
Sabetta J.R.,Greenwich Hospital |
Depetrillo P.,Wake forest University |
Cipriani R.J.,Greenwich Hospital |
And 3 more authors.
PLoS ONE | Year: 2010
Background: Declining serum concentrations of 25-hydroxyvitamin D seen in the fall and winter as distance increases from the equator may be a factor in the seasonal increased prevalence of influenza and other viral infections. This study was done to determine if serum 25-hydroxyvitamin D concentrations correlated with the incidence of acute viral respiratory tract infections. Methodology/Findings: In this prospective cohort study serial monthly concentrations of 25-hydroxyvitamin D were measured over the fall and winter 2009-2010 in 198 healthy adults, blinded to the nature of the substance being measured. The participants were evaluated for the development of any acute respiratory tract infections by investigators blinded to the 25-hydroxyvitamin D concentrations. The incidence of infection in participants with different concentrations of vitamin D was determined. One hundred ninety-five (98.5%) of the enrolled participants completed the study. Light skin pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of 25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p<0.0001) two-fold reduction in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill. Conclusions/Significance: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least during the fall and winter in temperate zones. The findings of the present study provide direction for and call for future interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin D concentrations, such as pregnant women, dark skinned individuals, and the obese. © 2010 Sabetta et al.
Keall R.,University of Sydney |
Clayton J.M.,Greenwich Hospital |
Butow P.,University of Sydney
Journal of Clinical Nursing | Year: 2014
Aims and objectives: To investigate the facilitators, barriers and strategies that Australian palliative care nurses identify in providing existential and spiritual care for patients with life-limiting illnesses. Background: Palliative care aims to be holistic, incorporating all domains of personhood, but spiritual/existential domain issues are often undertreated. Lack of time and skills and concerns for what you may uncover hamper care provision. Design: A qualitative study through semistructured interviews. Methods: We interviewed 20 palliative care nurses from a cross section of area of work, place of work, years of experience, spiritual beliefs and importance of those beliefs within their lives. Questions focused on their current practices of existential and spiritual care, identification of facilitators of, barriers to and strategies for provision of that care. Their responses were transcribed and subjected to thematic analysis. Results: The nurses' interviews yielded several themes including development of the nurse-patient relationship (14/20 nurses), good communication skills and examples of questions they use to 'create openings' to facilitate care. Barriers were identified as follows: lack of time (11/20 nurses), skills, privacy and fear of what you may uncover, unresolved symptoms and differences in culture or belief. Novel to our study, the nurses offered strategies that included the following: undertaking further education in this area, being self-aware and ensuring the setting is conducive to in-depth conversations and interactions and documentation and/or interdisciplinary sharing for continuity of care. Conclusion: Palliative care nurses are well placed to provide existential and spiritual care to patients with the primary facilitator being the nurse-patient relationship, the primary barrier being lack of time and the primary strategy being undertaking further education in this area. Relevance to clinical practice: These findings could be used for nurse-support programmes, undergraduate or graduate studies or communication workshop for nurses. © 2014 John Wiley & Sons Ltd.
Best M.,University of Sydney |
Best M.,Greenwich Hospital |
Butow P.,University of Sydney |
Olver I.,Cancer Council Australia
Supportive Care in Cancer | Year: 2014
Purpose: Spiritual care is reported as important for cancer patients, but the role of the doctor in its provision is unclear. We undertook to understand the nature of spiritual support for Australian cancer patients and their preferences regarding spiritual care from doctors. Methods: Using grounded theory, semistructured interviews were conducted with 15 cancer patients with advanced disease in a variety of care settings. Patients were asked about the source of their spiritual support and how they would like their doctors to engage with them on spiritual issues. Results: Three themes were identified as follows: (1) sources of spiritual support which helped patients cope with illness and meet spiritual needs, (2) facilitators of spiritual support, and (3) role of the doctor in spiritual support. Regardless of religious background, the majority of patients wanted their doctor to ask about their source of spiritual support and facilitate access to it. Patients did not want spiritual guidance from their doctors, but wanted to be treated holistically and to have a good relationship, which allowed them to discuss their fears. Doctors' understanding of the spiritual dimension of the patient was part of this. Conclusions: Spirituality is a universal phenomenon. Patients in a secular society want their doctor to take an interest in their spiritual support and facilitate access to it during illness. © 2013 Springer-Verlag.
DeLong A.K.,Brown University |
Blossom B.,Colorado State University |
Maloney E.L.,Partnership for Healing and Health Ltd. |
Phillips S.E.,Greenwich Hospital
Contemporary Clinical Trials | Year: 2012
Introduction: Lyme disease (Lyme borreliosis) is caused by the tick-borne spirochete Borrelia burgdorferi. Long-term persistent illness following antibiotic treatment is not uncommon, particularly when treatment is delayed. Current treatment guidelines for persistent disease primarily rely on findings from four randomized, controlled trials (RCTs), strongly advising against retreatment. Methods: We performed a biostatistical review of all published RCTs evaluating antibiotic retreatment, focusing on trial design, analysis and conclusions. Results: Four RCTs met the inclusion criteria; all examined the efficacy of intravenous ceftriaxone versus placebo at approximately 3 or 6. months. Design assumptions for the primary outcomes in the two Klempner trials and two outcomes in the Krupp trial were unrealistic and the trials were likely underpowered to detect clinically meaningful treatment effects. The Klempner trials were analyzed using inefficient statistical methods. The Krupp RCT was well-designed and analyzed for fatigue, finding statistically significant and clinically meaningful improvement. Fallon corroborated this finding. Fallon also found improvement in cognitive functioning, a primary outcome, at 12. weeks which was not sustained at 24. weeks; improvements in physical functioning and pain were demonstrated at week 24 as an interaction effect between treatment and baseline symptom severity with the drug effect increasing with higher baseline impairment. Discussion: This biostatistical review reveals that retreatment can be beneficial. Primary outcomes originally reported as statistically insignificant were likely underpowered. The positive treatment effects of ceftriaxone are encouraging and consistent with continued infection, a hypothesis deserving additional study. Additional studies of persistent infection and antibiotic treatment are warranted. © 2012 Elsevier Inc.
Best M.,Greenwich Hospital |
Best M.,University of Sydney |
Butow P.,University of Sydney |
Olver I.,Cancer Council Australia
Palliative Medicine | Year: 2014
Results: Patients were observed to be along a spectrum between having peace and not having peace. Features of the two extreme positions are described. Doctors could facilitate peace by developing a good relationship with cancer patients and supplying clear and honest information about what patients could expect as they approached their death.Conclusion: Spiritual well-being in cancer patients can be promoted by communication from doctors regarding prognosis, which allows them time to prepare for death, and recognition of their fears. However, acceptance of death does not always lead to the patient experiencing peace.Background: Being at peace is important for the quality of life of dying cancer patients, but its features, and the role of the doctor in facilitating peace, are unclear.Aim: We sought to understand the features of a peaceful patient, and patients' preferences regarding the role of the doctor in facilitating a sense of peace.Design: A grounded theory approach was used with semi-structured interviews. Patients were asked about the things that gave their life meaning and a sense of peace and how the doctor could support their spiritual well-being. Patients were also questioned about their concerns for their future.Setting/participants: In total, 15 cancer patients with advanced disease were interviewed in a variety of care settings. © The Author(s) 2014.